International Stem Cell Corp., a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs), announced this morning that it will present results of pre-clinical studies of Parkinson’s disease (PD) at the 65th American Academy of Neurology Annual Meeting at the San Diego Convention Center, San Diego, California, on Wednesday, March 20th, 2013.
At the meeting Dr. Ruslan Semechkin, Vice President of Research and Development for ISCO, will present results from efficacy studies of stem cell derived neuronal cells for the treatment of Parkinson’s disease. Results and conclusions from both rodent and non-human primate models of the disease will be presented.
One of the world’s most important annual events for neurologists and neuroscience professionals, the American Academy of Neurology Annual Meeting is the largest international meeting of its kind with more than 12,000 attendees at last year’s meeting.
For more information, visit www.intlstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment